# White Cross

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/white-cross

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: www.whitecross.jp
- Total disclosed funding: $3.5M
- Latest round: Series B (Jul 8, 2022)
- Investors on record: 4

## About

Based in Japan, White Cross operates and provides innovative healthcare solutions, focusing on medical devices and diagnostic equipment aimed at improving patient care and optimizing clinical workflows.White Cross is a healthcare technology company specializing in medical devices and diagnostic tools. Founded in 2015 and headquartered in Tokyo, Japan, White Cross has completed a total of 4 deals, with its most recent deal occurring on July 8, 2022, during which it raised JPY 300 million in Series B funding. Investors in this round included CRG Investment Co., Ltd., Morita, Nissay Capital, and SMBC Venture Capital. The funds raised will bolster new business activities, marketing efforts, and recruitment to support the company's expansion. The company was founded by industry professionals who have a rich history in the healthcare technology sector.White Cross specializes in providing innovative healthcare solutions, focusing primarily on medical devices and diagnostic equipment designed to enhance patient care and streamline clinical workflows. Their core product offerings include advanced imaging systems and point-of-care testing solutions, which facilitate rapid diagnosis and treatment of various medical conditions. These products are strategically designed to address critical end-use cases in hospitals, clinics, and outpatient facilities, ensuring that healthcare providers can deliver timely and accurate medical interventions. White Cross has successfully penetrated key geographical markets, including regions in Asia and North America, catering to a diverse clientele that encompasses public and private healthcare institutions, as well as individual healthcare practitioners.White Cross generates revenue through a combination of direct sales and strategic partnerships with healthcare providers and institutions. The transactional structure typically involves B2B arrangements, where healthcare organizations procure medical devices and diagnostic tools directly from the company. Clients engage in subscription models for ongoing services, including maintenance and software updates, which are critical to ensuring the devices operate at optimal efficiency. Flagship products, which are crucial to the company's portfolio, contribute significantly to the revenue stream through both initial sales and recurring service contracts. Specific pricing plans are established based on the product offerings and the unique needs of each client, allowing for tailored solutions that maximize the value delivered to end users.Following the Series B funding round on July 8, 2022, White Cross plans to leverage the JPY 300 million raised to enhance its business operations, focus on marketing, and support recruitment initiatives. The company is designing new products aimed at further improving patient care, with plans to launch these innovations in the coming year. Additionally, White Cross is targeting expansion into emerging markets in Southeast Asia and Latin America by 2025, aiming to increase their global footprint and accessibility of their healthcare solutions.

## Funding rounds

- Series B, Jul 8, 2022, $2.2M — SMBC Venture Capital, Nissay Capital, CRG Investment Co., Ltd., Morita
- Series A, Sep 7, 2017, $1.3M — Nissay Capital

## Investors

- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A, Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- CRG Investment Co., Ltd. — Series B
- Morita — Series B